Follow Us TR

News Details

Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain

About Lexicon Pharmaceuticals, Inc.
  • NASDAQ: $LXRX
  • Notified: $1.65
  • 08:00 EDT

Price Chart